Access
Email Verification
Agenda 2023
DAY 1: TBC
0830 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 RESERVED PRESENTATION
1010 - 1040 THE NO-WIN CHOICES AN AMR PATIENT AND FOUNDER FACES
- Highlighting the struggle faced by AMR patients
- Looking at the uphill battle for funding that faces AMR companies
- Implementing bottom-up incentives that encourage innovation
Bradley Burnam
Turn Therapeutics
Turn Therapeutics
1040 - 1100 MORNING COFFEE BREAK IN THE EXHIBIT AREA
1100 - 1130 INSTRUMENT-FREE MOLECULAR DIAGNOSTICS FOR HOME APPLICATIONS
- Understand the decentralization strategy of diagnostics lab equipment to Home and Point-of-Care
- Introducing low-cost home diagnostics test to determine if it is a virus or bacteria infection
- Learn how to target the right antibiotic by using rapid diagnostics with molecular accuracy
Mohamed Azize
Analog Devices, Inc.
Analog Devices, Inc.
1130 - 1200 THE POWER OF REAL-WORLD INSIGHTS IN ANTIMICROBIAL STEWARDSHIP
- Adopting pragmatic uses of RWD and technology to enable over/inappropriate prescription patterns
- Enabling assessment of the appropriateness of antibiotic prescribing aligned with HEDIS measures
- Facilitating the use of technology to drive actionable insights and interventions
Nandini Selvam
IQVIA Government Solutions
IQVIA Government Solutions
1200 - 1330 NETWORKING LUNCH & VISIT THE GLOBAL AMR SUMMIT EXHIBITION
1330 - 1400 NUCLEASE BIOMARKER-BASED RAPID ANTIBIOTIC SUSCEPTIBILITY TESTS
- Understand how Nucleases can serve as biomarkers for infectious diseases
- Learn how bacterial pathogens can be detected via fluorogenic substrates for nucleases
James McNamara
Nuclease Probe Technologies, Inc.
Nuclease Probe Technologies, Inc.
1400 - 1430 RESERVED PRESENTATION
1430 - 1500 DESIGN AND EVALUATION OF CYCLOTIDE-BASED ANTIMICROBIAL MICRO-PROTEINS
- Design, synthesis, and structural characterization of an engineered cyclotide MCo-PG2
- Looking at antimicrobial activity of MCo-PG2 in vitro against different ESKAPE pathogens
- Understanding the toxicity profile of MCo-PG2 in vivo
Julio Camarero
University of Southern California
University of Southern California
1500 - 1530 AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
1530 - 1600 SAFETY AND THE EFFICACY OF BACTERIOPHAGE COP-80B FOR PROSTHETIC JOINT INFECTIONS
- Learn in-vitro and in-silico bacteriophage COP-80B characterization
- Development of mice model (implant optimization, surgery protocol)
- Evaluating the efficacy of COP-80B for treatment of prosthetic joint infection in mice model
Matjaz Peterka
COBIK
COBIK
1600 - 1630 A MORBIDOSTAT-BASED EXPERIMENTAL EVOLUTION OF ANTIBIOTICS RESISTANCE
- Learn more about the experimental evolution of a continuous culturing device, morbidostat
- Understand deep sequencing of evolving populations in time series with 1000 genomic coverage
- Explore clone-level analysis isolation, sequencing, resistance(MIC), fitness of selected clones
Andrei Osterman
Sanford Burnham Prebys
Sanford Burnham Prebys
1630 - 1700 USING PLANTS AS AN EXPRESSION PLATFORM TO PRODUCE A NOVEL ANTIVIRAL TO COVID-19
- Exploring plants as a production platform for the expression of pharmaceutical proteins
- Understand how novel antiviral peptides inhibit virus replication completely
- Demonstrating the power of plant molecular farming
Kathleen Hefferon
Cornell University
Cornell University
1700 - 1800 NETWORKING DRINKS RECEPTION
DAY 2: TBC
0900 - 0930 MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 RESPONSE TO ANTIBIOTICS IMPROVES OPTIMAL SELECTION OF ANTIBIOTIC THERAPY
- Introducing AtbFinder, a proprietary platform technology for antimicrobial susceptibility testing
- Learn the selection of the most efficacious antibiotic therapy for drug-resistant bacterial infections
- Know how AtbFinder selects antibiotics that treat the bacterial community as a whole
George Tetz
Human Microbiology Institute
Human Microbiology Institute
1010 - 1040 OVERCOMING AMR: DEVELOPMENT OF NEW VACCINES, THERAPEUTICS, AND DIAGNOSTICS
- Understand the development and regulatory approval of new vaccines
- Introducing new products that support the battle against AMR
- Learn more about our ongoing programme of new standard development
Neil Almond
NIBSC
NIBSC
1040 - 1110 CAS CONTENT COLLECTION TO REVIEW ADVANCEMENTS IN TREATING MICROBIAL INFECTION
- Looking at the patent landscape view of novel antibiotics
- Advances in novel chemical structures being studied as antibiotics
- Evaluating biologics in treating a microbial infection
Angela Zhou Qiongqiong
CAS
CAS
1110 - 1130 MORNING COFFEE BREAK IN THE EXHIBIT AREA
1130 - 1200 RESERVED PRESENTATION
1200 - 1230 TELE-STEWARDSHIP IMPLEMENTATION AND BENEFITS
- Updates on the advancement of the nascent field of tele-stewardship
- Looking at the models and examples of tele-stewardship programs
- Understand logistical challenges and solutions to implementing a tele-stewardship program
Matthew Davis
Infectious Disease Connect, Inc.
Infectious Disease Connect, Inc.
1230 - 1300 PROTEOMICS, BIOINFORMATICS, AND COMBINATORIAL GONORRHEA VACCINE STRATEGIES
- Introducing immunoproteomics coupled with broad-ranging bioinformatics of antigen conservation
- Learn combinatorial gonorrhea vaccine strategies to identify the most effective vaccines
Aleksandra Sikora
Oregon State University
Oregon State University
1300 - 1315 FEEDBACK & RAFFLE DRAW
1315 - 1430 NETWORKING LUNCH
Key topics for 2023:
- The future of drug development and vaccines to combat infections
Understanding the mechanisms and drivers of antimicrobial resistance and fighting antimicrobial resistance through novel antimicrobials and vaccines. - New developments in protein folding to curb antimicrobial resistance
Explore more about the omics of antimicrobial resistance and disrupting extra cytoplasmic protein folding as molecular tools to fight antimicrobial resistance. - Latest research in antimicrobial photodynamic therapy as a molecular tool
Assessing the advances in photodynamic antimicrobial chemotherapy by conjugating biomaterials with photosensitizers as a molecular tool for antimicrobial resistance. - The role of AI in the design and development of next-generation antimicrobials
Looking at the role of artificial intelligence in advancing the design and discovery of novel artificial antimicrobials. - Advances in antimicrobial peptides and the development of novel antibiotics
Achieve a deeper understanding of drug repurposing in the development developing of novel antimicrobials, antimicrobial peptides, and quorum-sensing inhibitors as future strategies in antibacterial agent design. - Global surveillance programs and stewardship platforms to control AMR
Learn how surveillance programs and stewardship platforms can drive change in AMR and the importance of collaboration with politicians and policymakers to control AMR.